MAM
OMED

Meeder Asset Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Meeder Asset Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,084
Closed -$7K – 1923
2018
Q3 		$7K Buy
3,084
+1,563
+103% +$3.74K ﹤0.01% 1276
2018
Q2 		$3.51K Sell
1,521
-295
-16% -$859 ﹤0.01% 1331
2018
Q1 		$6K Buy
1,816
+720
+66% +$1.98K ﹤0.01% 1207
2017
Q4 		$4K Sell
1,096
-250
-19% -$1.09K ﹤0.01% 1412
2017
Q3 		$6K Buy
1,346
+547
+68% +$2.22K ﹤0.01% 1249
2017
Q2 		$3K Sell
799
-917
-53% -$3.81K ﹤0.01% 1376
2017
Q1 		$16K Sell
1,716
-1,259
-42% -$11.1K ﹤0.01% 766
2016
Q4 		$23K Buy
+2,975
New +$27.3K ﹤0.01% 637

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Meeder Asset Management's OMED Position: Q4 2018 in Review

Meeder Asset Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 3,084 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in OMED in Q4 2016 and held it in 8 quarters. The position peaked at $23K in Q4 2016. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Meeder Asset Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Meeder Asset Management sold 3,084 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $7K.
  • Meeder Asset Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2016 and held it in 8 quarters.
  • Meeder Asset Management's OncoMed Pharmaceuticals, Inc. position peaked at $23K in Q4 2016.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Meeder Asset Management's 13F filing for Q4 2018, filed 17 Jan 2019.